The Alder Research Group has received an R01 grant the National Institute of Aging (R01AG065879, “First-in-class Peptide Therapeutics for Mitochondrial Disorders: Molecular Mechanism of Action and Optimization of Design”). This is a five-year grant in the amount of $2.5M to support the development and analysis of therapeutic compounds for aging-related mitochondrial disorders.
We have received a $50K grant from the Barth Syndrome Foundation, “Development of Mitochondria-Targeted Peptide Compounds as Barth Syndrome Therapeutics. This work will explore a library of compound variants optimized as therapeutics for treating dysfunctional lipid biogenesis of Barth Syndrome patients.
The Alder Group has received an R01 grant from NIH General Medical Sciences (R01GM136975 , “Mitochondrial Membrane Compartmentalization”) for $774K over two years. This is a multi-PI grant with the group of Dr. Steven Claypool from the Johns Hopkins University School of Medicine.
PhD candidate Melissa Brundin has completed her dissertation “Investigation of the Protein-Membrane Interactions of the Tim23 Channel Subunit” and did a remarkable job at her defense. Congratulations, soon-to-be Dr. Brundin!
Wayne Mitchell passed his qualifying exam and is now an official PhD candidate. Congratulations, Wayne!
Sally Chamberland is a newly-minted PhD from the Alder Lab. Congratulations, Dr. Chamberland!